Compare Revvity Inc (RVTY) vs Trade Desk Inc (TTD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Revvity Inc vs Trade Desk Inc — how do they compare? Revvity Inc trades at $124.14 (market cap $14.18B), while Trade Desk Inc trades at $13.92 (market cap $6.59B). The key difference: Revvity Inc is far larger — about 2.2× Trade Desk Inc's market cap, and Revvity Inc pays a 0.22% dividend while Trade Desk Inc pays none. Which is the better fit depends on your goals.
| RVTY | TTD | |
|---|---|---|
Market Cap | $14.18B | $6.59B |
Sector | Technology | Technology |
52-Week High | $130.94 | $54.13 |
52-Week Low | $82.26 | $13.03 |
Enterprise Value | $16.50B | $5.54B |
Dividend Yield | 0.22% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RVTY trades at $127.08, down 2.41% on the day, with a bullish technical signal from moving averages and strong support at $126. The company reported Q2 2026 EPS of $1.41, beating estimates, and raised its full-year outlook, driven by diagnostics strength and improved cash flow. Recent news includes the acquisition of Human Cell Design and the launch of the SuperFlex prenatal screening system.
Outlook is positive with 52% analyst buy ratings and a $135.25 consensus price target, implying ~6% upside. Risks include a premium valuation (P/E 61.1) and execution of growth initiatives. Strong institutional interest, such as Bank of New York Mellon's $78.77 million investment, supports confidence in the stock's trajectory.
The Trade Desk (TTD) trades at $14.02, down 2.84% amid bearish technical signals and recent earnings misses. The stock faces headwinds from slowing revenue growth (3% in Q2 2026) and a 15% workforce reduction announced in September 2026. Despite solid profitability margins (net margin 13.61%) and reasonable valuation (P/E 16.69), negative cash flow trends and competitive pressures weigh on sentiment. Technical indicators show resistance at $15 with support at $13-14, while analyst consensus remains mixed with a $14.07 price target.
Outlook: TTD's long-term ad-tech positioning and AI innovations (Kokai Zuma) offer growth potential, but near-term execution risks and macro ad demand softness pose challenges. Investors should monitor Q3 earnings and restructuring efficacy for catalysts. Risks include heightened competition and reliance on digital ad spending cycles.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Revvity Inc
Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.
Read more on RVTY →About Trade Desk Inc
The Trade Desk Inc is engaged in providing a technology platform for ad buyers. Through its cloud-based platform ad buyers can create, manage, and optimize data-driven digital advertising campaigns across ad formats and channels, including display, video, audio, in-app, native and social, on a multitude of devices. Its products include Data Management Platform, Cross-Device Targeting, Video Advertising, Mobile Advertising, and others.
Read more on TTD →
